RxDoctor Payments Data

Lorraine Kossol, APRN

Nurse Practitioner · Las Vegas, NVNPI 1720333818

Payments from drug & device makers

$1,051in general payments, 2019–2025

Across 21 payments — averaging $50.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$171
  • Actelion Pharmaceuticals US, Inc.$149
  • GSK$141
  • Boehringer Ingelheim$125
  • Grifols USA, LLC$125
  • United Therapeutics Corporation$95
  • plus $245 from 6 others

What the payments were for

  • Food & beverage$1,01697%
  • Education$353%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,051 in reported general payments places this provider in the 70th percentile of 933 nurse practitioner providers in Nevada.

See all nurse practitioner providers in Nevada

Medicare billing

Part B allowed, 2024
$172,605
Medicare patients
497
Services billed
4,062

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter124$124,804
Breztri AerosphereBudesonide/Glycopyr/Formoterol56$36,979
Breo ElliptaFluticasone/Vilanterol65$28,675
Spiriva RespimatTiotropium Bromide25$15,022
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$12,420
Spiriva HandihalerTiotropium Bromide21$10,757
SymbicortBudesonide/Formoterol Fumarate26$9,532
Fluticasone-SalmeterolFluticasone Propion/Salmeterol41$8,185
Tiotropium Bromide12$8,001
Stiolto RespimatTiotropium Br/Olodaterol Hcl17$7,975
DuleraMometasone/Formoterol14$6,319
Advair HfaFluticasone Propion/Salmeterol16$5,005
Wixela InhubFluticasone Propion/Salmeterol43$4,282
Albuterol Sulfate HfaAlbuterol Sulfate106$3,643
Ventolin HfaAlbuterol Sulfate13$1,529

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$141$165,899207 claims
AstraZenecaBreztri Aerosphere, Symbicort$92$46,51182 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$125$22,99742 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 933 nurse practitioner providers in Nevada.

Other nurse practitioner in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →